Smart Blood Analytics Swiss has received the European Medical Device Regulation (EU-MDR) certification for their VIRUS vs. BACTERIA Clinical Decision Support Software.

The advanced medical tool sets a new benchmark in accurately distinguishing between viral and bacterial infections and helps physicians deliver targeted treatment to patients.

The VIRUS vs. BACTERIA model is the first Clinical Decision Support Software to receive EU-MDR certification in the infectious disease management area.

It leverages only 17 routine blood parameters, biological sex, and age to distinguish between viral and bacterial infections.

With routine blood testing being available worldwide, the VIRUS vs. BACTERIA model expands the physician’s capability to differentiate between viral and bacterial infections.

aids in the rational use of antibiotics, especially in the range where other commonly used blood markers offer limited diagnostic value.

Smart Blood Analytics Swiss CEO Marko Notar said: “This achievement shows our commitment to advancing healthcare through innovation.

“By providing clinicians with a precise tool to differentiate between viral and bacterial infections, we aim to empower doctors with more information and help them in their decision of antibiotic prescriptions. This contributes to more effective healthcare practices.”

The clinical decision support software represents Smart Blood Analytics Swiss’ significant step towards preventing antimicrobial resistance (AMR).

AMR, primarily driven by the misuse and overuse of antibiotics, is a significant threat to global public health and development, causing millions of deaths each year.

It undermines the effectiveness of treatments for infectious diseases, putting modern medical advancements at risk and increasing healthcare costs substantially.

Smart Blood Analytics Swiss said that the idea to develop VIRUS vs. BACTERIA was inspired by the 2022 G20 Bali summit, where a Call to Action on antimicrobial resistance was presented.

The event convened the leaders worldwide, to address the challenges and highlighted the importance of collaborative efforts to develop effective strategies for infection management.